Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Avisa Diagnostics Inc FOGCF

Avisa Diagnostics Inc. is a clinical-stage medical device company. The Company is engaged in the development of the Allora BreathTest (ABT), a drug/device biomarker technology platform. The Allora BreathTest (ABT) is an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load. ABT enables the ultra-rapid detection of virulent bacterial pathogens... see more

GREY:FOGCF - Post Discussion

Avisa Diagnostics Inc > I FEEL AVISA HAS A BETTER TECHNOLOGY AND FURTHER AHEAD.
View:
Post by frewil11 on Jan 30, 2021 12:51pm

I FEEL AVISA HAS A BETTER TECHNOLOGY AND FURTHER AHEAD.

https://www.bbc.com/news/uk-wales-54718848
Comment by Mcgirt on Jan 30, 2021 1:35pm
That's exactly what I was thinking/hoping would happen with the Avisa device...be converted to detect Covid 19 with a breath test. There are many similarities here. Good find frewil.    "Originally, the technology was being used to develop tests to detect illnesses such as lung cancer, and how to distinguish between bacterial and viral respiratory diseases quickly ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities